Inogen (NASDAQ:INGN) Issues Q1 2021 Earnings Guidance

Inogen (NASDAQ:INGN) updated its first quarter 2021 earnings guidance on Tuesday. The company provided EPS guidance of – for the period. The company issued revenue guidance of $84 million-$87 million, compared to the consensus revenue estimate of $78.62 million.

Shares of NASDAQ:INGN traded down $1.13 on Tuesday, hitting $67.09. The company had a trading volume of 166,493 shares, compared to its average volume of 158,042. The firm’s 50-day simple moving average is $56.45 and its two-hundred day simple moving average is $45.84. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -745.36 and a beta of 1.05. Inogen has a 1 year low of $26.57 and a 1 year high of $68.41.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Wednesday, February 24th. The medical technology company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. Inogen had a negative net margin of 0.66% and a positive return on equity of 0.21%. The business had revenue of $73.98 million during the quarter, compared to analyst estimates of $69.19 million. As a group, research analysts forecast that Inogen will post -0.31 EPS for the current fiscal year.

A number of research firms have issued reports on INGN. Zacks Investment Research upgraded Inogen from a sell rating to a hold rating and set a $59.00 price objective for the company in a report on Monday, February 15th. SVB Leerink lifted their price target on shares of Inogen from $47.00 to $54.00 and gave the company a market perform rating in a research report on Wednesday, March 3rd. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $62.00.

In other news, EVP Brenton Taylor sold 2,841 shares of the company’s stock in a transaction that occurred on Thursday, April 15th. The shares were sold at an average price of $65.21, for a total value of $185,261.61. Following the transaction, the executive vice president now owns 59,774 shares in the company, valued at $3,897,862.54. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Alison Bauerlein sold 1,200 shares of the firm’s stock in a transaction that occurred on Tuesday, April 13th. The shares were sold at an average price of $60.00, for a total transaction of $72,000.00. Following the sale, the chief financial officer now directly owns 4,524 shares of the company’s stock, valued at approximately $271,440. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,707 shares of company stock worth $4,128,568. Insiders own 4.83% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: The four types of profit margin

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with's FREE daily email newsletter.